Funder
National Key Research and Development Program of China
National Natural Science Foundation of China
Shanghai Rising-Star program
Development Fund for Shanghai Talents
Young Talent Supporting Program of China Association of Traditional Chinese Medicine
Hundred Talents Program of Shaanxi
Shanghai Development Office of TCM
Shanghai Shen Kang Hospital Development Center
Budget project of Shanghai University of Traditional Chinese Medicine
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference85 articles.
1. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
2. American Cancer Society. Cancer facts and figures 2015. Atlanta: American Cancer Society. 2015.
3. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic Virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–19.
4. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. The Lancet Oncology. 2017;18(1):31–41.
5. Antonia SJ, Gettinger SN, Chow LQM, Juergens RA, Borghaei H, Shen Y, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol. 2014;32:15.